首页> 外文期刊>International Journal of Clinical Oncology >Complete response of a patient with advanced gastric cancer, showing Epstein-Barr virus infection, to preoperative chemotherapy with S-1 and cisplatin
【24h】

Complete response of a patient with advanced gastric cancer, showing Epstein-Barr virus infection, to preoperative chemotherapy with S-1 and cisplatin

机译:表现为爱泼斯坦-巴尔病毒感染的晚期胃癌患者对术前用S-1和顺铂化疗的完全反应

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Here we report the case of a patient with advanced gastric cancer with esophageal invasion who was treated with chemotherapy using S-1 and cisplatin (CDDP) preoperatively. The patient was a 72-year-old woman who was diagnosed with advanced gastric cancer (T3N2M0) with esophageal invasion. S-1 was orally administered at 80 mg/day (60 mg/m2 per day) on days 1–14 and CDDP was infused at 80 mg/day (60 mg/m2 per day) on day 8, followed by a 1-week rest. Marked reductions in the sizes of the primary tumor and metastatic lymph nodes around the stomach were observed after two cycles of the therapy. Adverse reactions occurring during the therapy were only grade 2 gastrointestinal disorder and grade 1 leukocytopenia. Radiological and endoscopic examinations before surgery showed that a partial response (PR) had been achieved. The patient underwent curative surgery consisting of total gastrectomy, D2 lymph node dissection, and splenectomy. Her postoperative course was uneventful, without surgical complications. No gastric cancer cells were detected in the primary lesion or lymph nodes by immunohistochemical staining with cytokeratin, confirming a histological complete response (CR). As Epstein-Barr virus-encoded small RNA (EBER) had been detected by in-situ hybridization in the gastric cancer cells of a biopsy specimen, this tumor was diagnosed as an Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC), which was effectively treated with S-1 and cisplatin chemotherapy.
机译:在这里,我们报道一例患有食管浸润的晚期胃癌患者,该患者在术前使用S-1和顺铂(CDDP)进行了化疗。该患者是一名72岁的女性,被诊断患有食管浸润的晚期胃癌(T3N2M0)。在第1-14天以80 mg /天(每天60 mg / m2 )口服S-1,并在80毫克/天(每天60 mg / m2 )口服CD-1。第8天,然后休息1周。在两个疗程后,观察到胃部原发肿瘤和转移性淋巴结大小明显减少。治疗期间发生的不良反应仅为2级胃肠道疾病和1级白细胞减少症。手术前的放射学和内窥镜检查表明已达到部分缓解(PR)。该患者接受了根治性手术,包括全胃切除,D2淋巴结清扫和脾切除。术后过程平稳,无手术并发症。通过细胞角蛋白免疫组织化学染色,在原发灶或淋巴结中未检测到胃癌细胞,证实了组织学完全应答(CR)。由于在活检标本的胃癌细胞中通过原位杂交检测到爱泼斯坦-巴尔病毒编码的小RNA(EBER),因此该肿瘤被诊断为与爱泼斯坦-巴尔病毒(EBV)相关的胃癌(EBVaGC) ,已通过S-1和顺铂化疗有效治疗。

著录项

  • 来源
    《International Journal of Clinical Oncology》 |2007年第6期|472-477|共6页
  • 作者单位

    Department of Surgery Chiba-Hokusoh Hospital Nippon Medical School 1715 Kamagari Inbamura Chiba 270-1694 Japan;

    Department of Surgery Chiba-Hokusoh Hospital Nippon Medical School 1715 Kamagari Inbamura Chiba 270-1694 Japan;

    Department of Surgery Chiba-Hokusoh Hospital Nippon Medical School 1715 Kamagari Inbamura Chiba 270-1694 Japan;

    Department of Surgery Chiba-Hokusoh Hospital Nippon Medical School 1715 Kamagari Inbamura Chiba 270-1694 Japan;

    Department of Surgery Chiba-Hokusoh Hospital Nippon Medical School 1715 Kamagari Inbamura Chiba 270-1694 Japan;

    Department of Surgery Chiba-Hokusoh Hospital Nippon Medical School 1715 Kamagari Inbamura Chiba 270-1694 Japan;

    Department of Surgery Chiba-Hokusoh Hospital Nippon Medical School 1715 Kamagari Inbamura Chiba 270-1694 Japan;

    Department of Surgery Chiba-Hokusoh Hospital Nippon Medical School 1715 Kamagari Inbamura Chiba 270-1694 Japan;

    Department of Surgery Chiba-Hokusoh Hospital Nippon Medical School 1715 Kamagari Inbamura Chiba 270-1694 Japan;

    Department of Surgery Chiba-Hokusoh Hospital Nippon Medical School 1715 Kamagari Inbamura Chiba 270-1694 Japan;

    Department of Pathology Chiba-Hokusoh Hospital Nippon Medical School Chiba Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Epstein-Barr virus (EBV); Gastric cancer; Complete response (CR); Cisplatin (CDDP); S-1; Chemotherapy;

    机译:爱泼斯坦-巴尔病毒(EBV);胃癌;完全应答(CR);顺铂(CDDP);S-1;化学疗法;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号